KR940014428A - N-옥시카보닐 치환된 5'-데옥시-5-플루오르사이티딘 - Google Patents

N-옥시카보닐 치환된 5'-데옥시-5-플루오르사이티딘 Download PDF

Info

Publication number
KR940014428A
KR940014428A KR1019930027962A KR930027962A KR940014428A KR 940014428 A KR940014428 A KR 940014428A KR 1019930027962 A KR1019930027962 A KR 1019930027962A KR 930027962 A KR930027962 A KR 930027962A KR 940014428 A KR940014428 A KR 940014428A
Authority
KR
South Korea
Prior art keywords
deoxy
fluoro
cytidine
fluorocytidine
carbonyl
Prior art date
Application number
KR1019930027962A
Other languages
English (en)
Other versions
KR100347218B1 (ko
Inventor
모토히로 아라사키
히데오 이시츠카
이사미 구루마
마사노리 미와
치카코 무라사키
노부오 심마
이사오 우메다
Original Assignee
프리돌린 클라우스너, 롤란트 보러
에프. 호프만-라 로슈 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940014428(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프리돌린 클라우스너, 롤란트 보러, 에프. 호프만-라 로슈 에이지 filed Critical 프리돌린 클라우스너, 롤란트 보러
Publication of KR940014428A publication Critical patent/KR940014428A/ko
Application granted granted Critical
Publication of KR100347218B1 publication Critical patent/KR100347218B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

일반식(Ⅰ)의 화합물 및 일반식(Ⅰ)의 화합물의 수화물 또는 용매화물은 종양 치료에 이용될 수 있다.
상기식에서, R1은 포화되거나 불포화된 직쇄 또는 측쇄의 탄화수소 라디칼(여기서, 탄화수소 라디칼의 가장 긴 직쇄 탄화수소 라디칼의 탄소수는 3 내지 7이다), 또는 일반식 -(CH2)n-Y(여기서, Y가 사이클로 핵실 라디칼일 경우 n은 0 내지 4의 정수이거나 Y가 탄소수 1 내지 4의 저급 알콕시 라디칼 또는 페닐 라디칼일 경우 n은 2 내지 4의 정수이다)이고, R2는 수소원자 또는 생리학적 조건하에서 용이하게 가수분해 될 수 있는 라디칼이다.
이들은 일반식 R1-OCOCl(여기서, R1은 상기 정의한 바와 같다)의 화합물을 R2가 보호그룹인, 상기 일반식(Ⅰ)의 N4-비치환된 5′-데옥시-5-플루오로사이티딘과 반응시키고, 필요할 경우 보호그룹을 제거함으로써 제조할 수 있다.

Description

N-옥시카보닐 치환된 5′-데옥시-5-플루오르사이티딘
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 일반식(Ⅰ)의 화합물 및 이의 수화물 또는 용매화물.
    상기식에서, R1은 포화되거나 불포화된 직쇄 또는 측쇄의 탄화수소 라디칼(여기서, 탄화수소 라디칼의 가장 긴 직쇄 탄화수소 라디칼의 탄소수는 3 내지 7이다), 또는 일반식 -(CH2)n-Y(여기서, Y가 사이클로 헥실 라디칼일 경우 n은 0 내지 4의 정수이거나 Y가 탄소수 1 내지 4의 저급 알콕시 라디칼 또는 페닐 라디칼일 경우 n은 2 내지 4의 정수이다)이고, R2는 수소원자 또는 생리학적 조건하에서 용이하게 가수분해될 수 있는 라디칼이다.
  2. 제1항에 있어서, 하기 그룹으로부터 선택된 화합물: 5′-데옥시-5-플루오로-N4-(프로폭시카보닐)사이티딘, 5′-데옥시-5-플루오로-N4-(헥실옥시카보닐)사이티딘, 5′-데옥시-5-플루오로-N4-(이소펜틸옥시카보닐)사이티딘, 5′-데옥시-5-플루오로-N4-(네오펜틸옥시카보닐)사이티딘, 5′-데옥시-5-플루오로-N4-[(1, 1, 2-트리메틸프로폭시)카보닐]사이티딘, 5′-데옥시-N4-[(3, 3-디메틸부톡시)카보닐]-5-플루오로사이티딘, 5′-데옥시-5-플루오로-N4-[(1-이소프로필-2-메틸프로폭시)카보닐]사이티딘, 5′-데옥시-N4-[(2-에틸부틸)옥시카보닐]-5-플루오로사이티딘, N4-[(사이클로헥실메톡시)카보닐]-5′-데옥시-5-플루오로사이티딘, 5′-데옥시-5-플루오로-N4-[(2-페닐에톡시)카보닐]사이티딘, 2′, 3′-디-O-아세틸-5′-데옥시-5-플루오로-N4-(프로폭시카보닐)사이티딘, 2′, 3′-디-O-아세틸-N4-(부톡시카보닐)-5′-데옥시-5-플루오로사이티딘, 2′, 3′-디-O-벤조일-N4-(부톡시카보닐)-5′-데옥시-5-플루오로사이티딘, 2′, 3′-디-O-아세틸-5′-데옥시-5-플루오로-N4-(펜틸옥시카보닐)사이티딘, 2′, 3′-디-O-아세틸-5′-데옥시-5-플루오로-N4-(이소펜틸옥시카보닐)사이티딘, 2′, 3′-디-O-아세틸-5′-데옥시-5-플루오로-N4-(헥실옥시카보닐)사이티딘, 2′, 3′-디-O-아세틸-5′-데옥시-N4-[(2-에틸부틸)옥시카보닐]-5-플루오로사이티딘, 2′, 3′-디-O-아세틸-N4-[(사이클로헥실메톡시)카보닐]-5′-데옥시-5-플루오로사이티딘, 2′, 3′-디-O-아세틸-5′-데옥시-5-플루오로-N4-[(2-페닐에톡시)카보닐]사이티딘, 5′-데옥시-5-플루오로-N4-(이소부톡시카보닐)사이티딘, 5′-데옥시-5-플루오로-N4-[(2-프로필펜틸)옥시카보닐]사이티딘, 5′-데옥시-N4-[(2-에틸헥실)옥시카보닐]-5′-플루오로사이티딘, 5′-데옥시-5-플루오로-N4-(헵틸옥시카보닐)사이티딘, N4-[(2-사이클로헥실에톡시)카보닐]-5′-데옥시-5-플루오로사이티딘, N4-[(3-사이클로헥실프로필)옥시카보닐]-5′-데옥시-플루오로사이티딘, N4-(사이클로헥실옥시카보닐)-5′-데옥시-5-플루오로사이티딘, 5′-데옥시-5-플루오로-N4-[(3-페닐프로필)옥시카보닐]사이티딘, 및 5′-데옥시-5-플루오로-N4-[(2-메톡시에톡시)카보닐]사이티딘, 특히 N4-(부톡시카보닐)-5′-데옥시-5-플루오로사이티딘 및 5′-데옥시-5-플루오로-N4-(펜틸옥시카보닐)사이티딘.
  3. 활성성분으로서 제1항에 따른 일반식(Ⅰ)의 화합물, 또는 일반식(Ⅰ)의 화합물의 수화물 또는 용매화물을 함유함을 특징으로 하는, 특히 종양치료용의 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930027962A 1992-12-18 1993-12-16 N-옥시카보닐치환된5'-데옥시-5-플루오로사이티딘 KR100347218B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92121538.0 1992-12-18
EP?92121538.0? 1992-12-18
EP92121538 1992-12-18

Publications (2)

Publication Number Publication Date
KR940014428A true KR940014428A (ko) 1994-07-18
KR100347218B1 KR100347218B1 (ko) 2003-01-24

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930027962A KR100347218B1 (ko) 1992-12-18 1993-12-16 N-옥시카보닐치환된5'-데옥시-5-플루오로사이티딘

Country Status (41)

Country Link
US (1) US5472949A (ko)
EP (1) EP0602454B1 (ko)
JP (1) JP2501297B2 (ko)
KR (1) KR100347218B1 (ko)
CN (1) CN1035617C (ko)
AT (1) ATE137244T1 (ko)
AU (1) AU671491B2 (ko)
BG (1) BG61485B1 (ko)
BR (1) BR9305089A (ko)
CA (1) CA2103324C (ko)
CZ (1) CZ284788B6 (ko)
DE (1) DE69302360T2 (ko)
DK (1) DK0602454T3 (ko)
EE (1) EE03086B1 (ko)
ES (1) ES2086856T3 (ko)
FI (1) FI112365B (ko)
GE (1) GEP20074251B (ko)
GR (1) GR3020286T3 (ko)
HK (1) HK1005875A1 (ko)
HR (1) HRP931430B1 (ko)
HU (2) HU218291B (ko)
IL (1) IL108000A0 (ko)
IS (1) IS4108A (ko)
LT (1) LT3115B (ko)
LV (1) LV10625B (ko)
MY (1) MY109282A (ko)
NO (1) NO300066B1 (ko)
NZ (1) NZ250414A (ko)
PH (1) PH30168A (ko)
PL (1) PL174100B1 (ko)
RO (1) RO112619B1 (ko)
RU (2) RU2493162C1 (ko)
SA (1) SA93140409B1 (ko)
SI (1) SI9300648B (ko)
SK (1) SK281403B6 (ko)
SV (1) SV1993000080A (ko)
TW (1) TW372239B (ko)
UA (1) UA39158C2 (ko)
UY (1) UY23697A1 (ko)
YU (1) YU49411B (ko)
ZA (1) ZA939293B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
ES2185378T3 (es) * 1998-09-25 2003-04-16 Warner Lambert Co Quimioterapia de cancer con acetildinalina en combinacion con gemcitabina, capecitabina o cisplatina.
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
ES2273841T3 (es) 2000-02-28 2007-05-16 Pfizer Enterprises Sarl Combinacion sinergica para el tratamiento de cancer colorrectal.
AU2001246863A1 (en) * 2000-04-11 2001-10-23 Sayuri Yamada Curcumin compositions
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
BR0316238A (pt) * 2002-11-15 2005-10-11 Warner Lambert Co Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
EP1689404B9 (en) * 2003-11-13 2009-04-22 Pharma Mar, S.A.U. Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
ES2384267T3 (es) 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
HUE030235T2 (en) 2005-12-13 2017-04-28 Incyte Holdings Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
EP2137201A2 (en) * 2007-04-20 2009-12-30 Dr. Reddy's Laboratories Ltd. Process for preparing capecitabine
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
EP3000467B1 (en) 2009-04-06 2023-03-01 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EA020494B1 (ru) 2009-05-22 2014-11-28 Инсайт Корпорейшн 3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ]ОКТАН- ИЛИ ГЕПТАННИТРИЛ КАК JAK-ИНГИБИТОРЫ
WO2011010967A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for producing flurocytidine derivatives
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
MX347851B (es) 2010-03-10 2017-05-16 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
HUE040107T2 (hu) 2010-03-12 2019-02-28 Genzyme Corp Kombinációs terápia mellrák kezelésére
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
SG190839A1 (en) 2010-11-19 2013-07-31 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
KR20220162825A (ko) 2012-11-15 2022-12-08 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
AU2014225938B2 (en) 2013-03-06 2018-07-19 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
SG11201601119XA (en) * 2013-08-20 2016-03-30 Incyte Corp Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
US10080807B2 (en) 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
CN111801339A (zh) * 2018-01-19 2020-10-20 纽科利制药公司 5-氟尿嘧啶化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
TWI797242B (zh) 2018-01-30 2023-04-01 美商英塞特公司 製備ｊａｋ抑制劑之方法及中間物
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
JP2022517352A (ja) 2019-01-11 2022-03-08 リポメディックス・ファーマシューティカルズ・リミテッド マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
JP2023523415A (ja) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자

Also Published As

Publication number Publication date
HRP931430A2 (en) 1998-06-30
CZ273193A3 (en) 1994-07-13
AU5069093A (en) 1994-06-30
CA2103324C (en) 1997-12-23
HK1005875A1 (en) 1999-01-29
IL108000A0 (en) 1994-04-12
JPH06211891A (ja) 1994-08-02
EP0602454A1 (en) 1994-06-22
EP0602454B1 (en) 1996-04-24
HU9303525D0 (en) 1994-04-28
FI935616A0 (fi) 1993-12-14
RU2493162C1 (ru) 2013-09-20
NO934671D0 (no) 1993-12-17
BR9305089A (pt) 1994-07-05
FI935616A (fi) 1994-06-19
PL301541A1 (en) 1994-06-27
HRP931430B1 (en) 1999-08-31
MY109282A (en) 1996-12-31
CA2103324A1 (en) 1994-06-19
ES2086856T3 (es) 1996-07-01
RU2135511C1 (ru) 1999-08-27
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
BG61485B1 (bg) 1997-09-30
NZ250414A (en) 1995-12-21
SK144493A3 (en) 1994-10-05
PH30168A (en) 1997-01-21
PL174100B1 (pl) 1998-06-30
CZ284788B6 (cs) 1999-03-17
IS4108A (is) 1994-06-19
SI9300648B (sl) 2000-06-30
NO934671L (no) 1994-06-20
KR100347218B1 (ko) 2003-01-24
LTIP1627A (en) 1994-07-15
AU671491B2 (en) 1996-08-29
LV10625B (en) 1996-04-20
TW372239B (en) 1999-10-21
GEP20074251B (en) 2007-12-10
GR3020286T3 (en) 1996-09-30
BG98304A (bg) 1994-01-03
HU211965A9 (en) 1996-01-29
DE69302360T2 (de) 1996-10-31
LV10625A (lv) 1995-04-20
JP2501297B2 (ja) 1996-05-29
HU218291B (en) 2000-07-28
SV1993000080A (es) 1996-01-26
DE69302360D1 (de) 1996-05-30
RU2458932C2 (ru) 2012-08-20
HUT65757A (en) 1994-07-28
YU77993A (sh) 1996-10-18
CN1094056A (zh) 1994-10-26
ZA939293B (en) 1994-06-18
UA39158C2 (uk) 2001-06-15
FI112365B (fi) 2003-11-28
DK0602454T3 (da) 1996-07-29
YU49411B (sh) 2006-01-16
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
SI9300648A (en) 1994-09-30
CN1035617C (zh) 1997-08-13
ATE137244T1 (de) 1996-05-15
UY23697A1 (es) 1994-06-08
EE03086B1 (et) 1998-04-15
LT3115B (en) 1994-12-27
NO300066B1 (no) 1997-04-01

Similar Documents

Publication Publication Date Title
KR940014428A (ko) N-옥시카보닐 치환된 5'-데옥시-5-플루오르사이티딘
RU93056196A (ru) N-карбонилзамещенные 5'-дезокси-5-фторцитидина
KR930006045A (ko) 항종양 활성을 가진 피리미딘 뉴클레오사이드, 그의 제조방법 및 용도
KR890014107A (ko) 백금 화학 요법약제
KR900001673A (ko) N-치환 아미드 유도체
KR890017309A (ko) 실온 경화성 조성물
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR890017315A (ko) 경화성 폴리오르가노 실록산 조성물
KR930007963A (ko) 안정화제로서 적당한 포스포러스 유기 아미드 화합물 및 이를 함유하는 중합체 조성물.
KR870007254A (ko) 프라이머(Primer) 조성물
KR880011141A (ko) 신규한 화합물
KR920701112A (ko) 플루오로-클로로-벤젠 유도체
KR900016270A (ko) 폴리올레핀 수지조성물
KR890001544A (ko) 뇌세포 보호작용을 가지는 의약 조성물
KR830004493A (ko) 섬유의 처리를 위한 실리콘 조성물
KR950003256A (ko) 헵타노에이트 유도체
TH14971A (th) N4-(สับสทิทิวต์-ออกซีคาร์บอนิล)-5-ดีออกซิ-5-ฟลูโอโร ไซดิดีน

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120628

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20130628

Year of fee payment: 12

EXPY Expiration of term